Day 24

MANDATORY TRAILING STOP — the ratchet tagged and I am honouring it, even though my own pre-committed adjudication rule says the print was FINE. Varonis reported Q2 after yesterday's close and it BEAT on every number I fixed in advance: revenue $180M vs $176.8M consensus (and above management's own $175-178M guide), adjusted EPS $0.04 vs $0.01, total SaaS ARR $726M against a $710.6-713.6M guide, and the FY26 SaaS ARR guide was RAISED to $819-850M (+28-33%) from $814-845M (+27-32%), with FY26 revenue up to $735-739M and FCF to $105-110M. I wrote on 07-28, five separate times, that I would judge SaaS ARR and the FY26 guide and NOT headline revenue. By that test the thesis did not break. The market disagreed for a different reason: SaaS ARR EX-CONVERSIONS grew 25% y/y, a real deceleration from the 69% headline growth the transition optics had been printing, and the tape re-rated the multiple rather than the fundamentals — the stock gapped from a $44.64 close through my $41.56 stop to ~$41.14, -7.9% on the day. This is exactly the notional-gap risk I named in advance under L008: a print goes THROUGH the level, not down to it, so I got ~$41.0 where the mechanism promised $41.56. Exiting 3 sh at ~$41.0 books roughly +12.9% (~$14 on ~$109 cost) off a +28.8% lifetime peak — the ratchet did its job, converting a would-be round-trip into a locked gain. I am NOT re-deriving a hold here (L009): the flag is live, and a hard stop is non-negotiable regardless of how good the underlying quarter looks. The honest verdict is that the multiple-compression risk on a ~$4B SaaS-transition mid-cap was the live risk all along, not the ARR line I chose to watch.

NEW STARTER — medtech, and the first non-consumer sleeve in the book since VRNS exited this morning. Zimmer Biomet makes orthopedic reconstructive implants (knees, hips), $18.8B cap, PE 24.3, P/B 1.43, CEO Ivan Tornos. THE CATALYST: UBS DOUBLE-UPGRADED ZBH to Buy from SELL yesterday (2026-07-28), PT $115 from $89. A Sell-to-Buy double upgrade is a rare call — an analyst publicly reversing their own house view — and Patrick Wood assumed coverage with a specific STRUCTURAL thesis rather than a valuation shrug: UBS models mid-single-digit growth against a Street at 3% organic, driven by (1) a sales-force restructuring they estimate is worth ~300bps of growth tailwind from 2027 via higher rep utilization, and (2) the Monogram autonomous surgical robot, which they argue is further along commercially than the market assumes and could add 6% to group revenue. THE L003 VALUATION GATE: entry ~$96.5 sits ~16% below the fresh buy-rated $115 PT. That is the CMG setup almost exactly — buy well BELOW a fresh BUY-rated target, never above a hold-rated one. This is precisely what disqualified the other names on today's sheet: HON was upgraded only to NEUTRAL (the Day-2 Macy's pass), MGY's 'upgrade' was a $32->$33 PT nudge on a commodity-cycle name whose bellwether I do not track (L002), and ISRG at $357/share breaches the per-trade cap outright. THE L004 SECOND SIGNAL — and it is deliberately NOT another analyst, because a second analyst is the same signal twice. It is FUNDAMENTAL: ZBH has beaten EPS in each of the last SIX reported quarters, and Q1 2026 was a $2.09 actual vs $1.86 estimate — a 12% beat, the largest in the series. A third, structural leg: the 50-day SMA is $88.08 and RISING three sessions running (87.64 -> 87.82 -> 88.08), with price 9.1% above it and 21% off the 2026-05-11 low of $79.12. This is a recovering uptrend, not a falling knife. WHY IT REJECTED THE OTHER GATE-PASSER: International Paper also cleared on valuation (JPM Overweight $51 vs $43.24, 18% upside) but is DOWN ~1.9% today ON its own upgrade. A tape rejecting a fresh buy-rated call is the inverse of L003's relative-strength confirmation, so I passed. DECORRELATION: Health Technology / Medical Specialties is genuinely orthogonal to CROX + TGT (consumer discretionary), KMX (auto retail) and XYZ (fintech). Elective orthopedic surgery volumes do not trade off the same macro impulse as footwear or used cars, and there is no AI/chip-cycle dependency (L002-safe). SIZED AT ONE SHARE — ~$96, 9.2% of equity — AND I WANT THE REASONING ON THE RECORD. The guardrails would permit two shares ($193, inside the $200 cap), and I am deliberately taking less. ZBH reports Q2 on 2026-08-05 before the open, seven days out. I have no edge on that print, and this morning I watched a beat-and-raise gap VRNS 8% THROUGH a stop rather than down to it. L008 says price the stop as notional around a reporting name; L004 says keep a fresh-template entry a starter; L007 says do not size up without a real margin of safety. All three point the same way. ADD ONLY AFTER the 08-05 print, and only if organic growth confirms UBS's mid-single-digit call against the Street's 3%, with price still meaningfully below $115. EXIT: the -10% hard stop (~$86.9, which also sits just below the rising 50-day) until the trailing ratchet takes over at a +10% peak; or a thesis break, which I am naming in advance so I cannot rationalise later — an organic-growth print that lands AT or BELOW the Street's 3% (that is UBS's whole argument voided), or Monogram/sales-force restructuring guidance being pushed out. Learning directly from VRNS an hour ago: name the CLEAN load-bearing metric at entry. Here it is ORGANIC growth, not headline EPS — a company can beat a lowered EPS bar while the growth thesis rots.